Progenics Pharmaceuticals Inc Net Income per Employee (PGNX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Progenics Pharmaceuticals Inc  (PGNX)
 

Progenics Pharmaceuticals Inc Net Income per Employee

PGNX's Quarterly Results, Trends, Rankings, Statistics
Progenics Pharmaceuticals Inc recorded a cumulative net loss of $-67 million during 12 month ending in the first quarter 2020.
The Healthcare sector has seen employees of 228 other companies achieving higher income per employee. While Progenics Pharmaceuticals Inc's total ranking has deteriorated compared to the previous quarter from 0 to 3811.


What is Income per Employee Ratio?






PGNX Net Income per Employee (Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -666,180 -685,520 -719,810 -774,960 -729,680
PGNX's Total Ranking # 3811 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


PGNX Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 229
Healthcare Sector # 557
Overall Market # 3811

Net Income per Employee Statistics
High Average Low
$ 107,330 $ -368,659 $ -774,960
(Dec 31 2016)   (Jun 30 2019)







Companies with similar Income per Employee for 12 month ending Mar 31 2020, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2020Number of Employees Mar 31 2020


Date modified: 2026-09-08T15:09:55+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.